AKT1 and neoplasm: Using AKT/NICD-induced spontaneous murine iCCA model, we found that anti-PD-1 therapy had limited suppressive effect on tumor initiation and progression, consistent with the clinical evidence that anti-PD-1 monotherapy is minimally effective in patients with iCCA.